( MENAFN - PR Newswire) Plasma-Based Proteomic Platform Predicts Clinical Benefit from Immune-Checkpoint Inhibitors in NSCLC, Melanoma, and HPV-Related Cancers BINYAMINA, Israel and CARY, N.C., May 23, 2024 /PRNewswire/ -- OncoHost , a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that it has been accepted for a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31 to June 4, 2024, in Chicago, Illinois.
The presentation will highlight the ability of the company's PROphet® platform to predict clinical benefit from immune checkpoint inhibitor (ICI)-based therapies across various cancer indications. "ICIs represent a key treatment modality for a growing number of cancer types, but a gap exists in the availability of predictive tests that can accurately identify patients likely to benefit from these therapies. Our PROphet® platform offers a solution," said Ofer Sharon, MD, CEO at OncoHost.
"This research highlights the adaptability of PROphet® as we work to provide treatment guidance for multiple indications. I am proud of our team's commitment to improving outcomes for cancer patients worldwide and the ongoing impact of our work in the oncology field." PROphet® is a novel and robust predictive computational model that analyzes and identifies proteomic profiles in pre- treatment blood plasma by combining bioinformatics, system biology, proteomi.